Cleo Diagnostics Expands Ovarian Cancer Test Biomarker Panel to Eight Markers Ahead of FDA Submission
核心洞察
Cleo Diagnostics (搜索) has expanded its Pre-Surgical Ovarian Cancer Test (搜索) biomarker panel from five to eight biomarkers to improve analytical robustness and manufacturing compatibility ahead of FDA 510(k) submission.
The optimized panel leverages the Ella™ platform's microfluidic cartridge architecture to enable simultaneous measurement of multiple biomarkers without compromising workflow efficiency or throughput.
The company has aligned with a manufacturing partner and expects to commence analytical validation activities immediately following execution of a binding manufacturing agreement.
Cleo Diagnostics (搜索) Limited has completed optimization of its Pre-Surgical Ovarian Cancer Test (搜索) biomarker panel, expanding from five to eight biomarkers to support commercial-scale deployment and regulatory progression toward FDA 510(k) submission. The enhanced panel improves analytical robustness, inter-assay reproducibility, and compatibility with manufacturing processes—key requirements for regulatory approval and wider clinical adoption.
The company's original biomarker panel demonstrated strong diagnostic performance in distinguishing benign from malignant ovarian disease, establishing a solid foundation for the development program. Cleo's patented CXCL10 (搜索) biomarker remains central to the panel and continues to underpin the company's proprietary technology.
Enhanced Platform Capabilities
Over the past six months, Cleo has undertaken expanded in-house assay development using the next-generation Ella™ immunoassay platform. The Ella™ platform's microfluidic cartridge architecture enables the simultaneous measurement of multiple biomarkers within a single sample, allowing expansion of the biomarker panel without compromising workflow efficiency, throughput, or sample utilization.
The inclusion of additional biomarkers reduces reliance on any single analyte and mitigates variability often observed in early-stage assay production. This significantly strengthens assay reproducibility and reduces technical risk ahead of analytical validation and regulatory submission.
Manufacturing Partnership and Regulatory Timeline
Cleo has worked closely with its preferred manufacturing partner to align on the revised panel. The partner brings established expertise in the development and production of assays for these biomarkers, significantly reducing scale-up and manufacturing risk.
A binding agreement for kit manufacturing to support analytical validation activities is expected imminently. Manufacturing of analytical validation lots is anticipated to commence immediately following execution of this agreement, supporting Cleo's planned FDA 510(k) submission.
"This represents a critical milestone in transitioning CLEO's Pre-Surgical Ovarian Cancer Test (搜索) from research into a commercial-ready kit," said Richard Allman, Cleo's Chief Executive Officer. "The expanded biomarker panel improves assay robustness and reproducibility under real-world conditions, whilst maintaining strong clinical performance."
US Market Entry Strategy
Cleo has outlined its United States commercialization and reimbursement plan for the Pre-Surgical Ovarian Cancer Test (搜索) ahead of anticipated FDA clearance. The company will launch in the US immediately after clearance using the existing miscellaneous CPT code 81599, allowing case-by-case billing and the capture of real-world utilization data that will underpin future reimbursement efforts.
Reimbursement for CPT code 81599 is negotiated payer by payer and is typically crosswalked to comparable multi-biomarker tests. Cleo cited existing ovarian cancer (搜索) assays, including OVA1 (搜索), which have reported reimbursement levels of $500 to $900 per test, as a reference framework for initial pricing discussions.
The short-term use of 81599 represents the first step toward applying for a dedicated CPT code through the AMA CPT Editorial Panel once sufficient utilization and supporting evidence have been assembled. A dedicated code is expected to improve reimbursement consistency and transparency, broaden payer coverage, and enable standardized utilization tracking.
Diagnostic Technology
Cleo is developing a simple blood test for the accurate and early diagnosis of ovarian cancer (搜索) based on the CXCL10 (搜索) biomarker, which is produced early and at high levels by malignant ovarian cancers but is largely absent in benign forms of the disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.
To support market access and evidence generation, the company is advancing health economics work, onboarding key opinion leaders, and planning real-world evidence collection during the initial rollout.